PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 85.92

Change

+0.64 (+0.75)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.51 (+0.33%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

+0.25 (+0.35%)

USD 3.01B
FXH First Trust Health Care AlphaD..

+0.83 (+0.75%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.22 (+0.25%)

USD 0.23B
IDNA iShares Genomics Immunology an..

+0.24 (+0.98%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.12 (+0.31%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

+0.57 (+0.60%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.52 (+1.80%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.58 (+0.93%)

USD 0.02B
FTXH First Trust Nasdaq Pharmaceuti..

+0.04 (+0.13%)

USD 0.02B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.90% 77% C+ 64% D
Dividend Return 0.76% 59% D- 15% F
Total Return 13.67% 82% B 58% F
Trailing 12 Months  
Capital Gain 17.00% 41% F 50% F
Dividend Return 1.05% 58% F 13% F
Total Return 18.05% 41% F 45% F
Trailing 5 Years  
Capital Gain 52.07% 64% D 70% C-
Dividend Return 4.23% 53% F 13% F
Total Return 56.30% 59% D- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.55% 57% F 60% D-
Dividend Return 7.14% 57% F 55% F
Total Return 0.59% 58% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.89% 67% D+ 70% C-
Risk Adjusted Return 55.40% 67% D+ 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike